#### **EXPORT LICENSE**

NRC FORM 250



## United States of America

Nuclear Regulatory Commission Washington, D.C. 20555 NRC LICENSE NO.: XMAT422/03

Page 1 of 7

NRC DOCKET NO.: 11005997

LICENSE EXPIRES: May 31, 2024

Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.

the state of the s	ell most lance llange llance llance llance l	AND STATE OF THE PROPERTY OF T
LICENSEE		ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)
Cambridge Isotope Laboratories Inc. 50 Frontage Road Andover, MA 01810		See following page(s)
Attn: Gary Ionta		
INTERMEDIATE CONSI	IGNEE(S) IN FOREIGN COUNTRY(IES)	OTHER U.S. PARTY(IES) TO EXPORT
See	e following page(s)	None
APPLICANT'S REFERENCE: Appl dated 02/02/2018  QUANTITY(IES)  DESCRIPTION		ULTIMATE DESTINATION: China
QUARTITI (ILU)	DESCRIPTION OF MATERIAL(S) OR FACILITY(IES)	
10,000 kilograms	This license is amended to include six additional ultimate consignees and extend the date of expiration from January 1, 2022 to May 31, 2024.	
	The licensee is authorized to export a cumulative total of 10,000 kilograms of deuterium, in the form of deuterium oxide, deuterium gas, and other compounds. The cumulative total starts from the issuance of original export license XMAT422.	
	CONDITION: A license amendment request is required for the addition of intermediate consignees not listed on this export license.	
Neither this license nor any right under this license shall be		

Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974.

This license is subject to the right of recapture or control by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of the NRC.

THIS LICENSE IS INVALID UNLESS SIGNED BELOW BY AUTHORIZED NRC REPRESENTATIVE

SIGNATURE:

Mohamed K. Shams S

NAME AND TITLE:

Mohamed K. Shams, Acting Deputy Director Office of International Programs

DATE OF ISSUANCE:

November 22, 2019

#### **ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

3.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

6.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

7.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

8.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

### **ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

10.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

12.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

14.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

16.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

#### **ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)




(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

## INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):


(for distribution to ultimate consignees)




(for distribution to ultimate consignees)





# INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):



















# INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):






(for distribution to ultimate consignees)



14. (for distribution to ultimate consignees)





17.

(for distribution to ultimate consignees)

# INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):



(for distribution to ultimate consignees)

19. (for distribution to ultimate consignees)

(for distribution to ultimate consignees)

21. (for distribution to ultimate consignous)

(for distribution to ultimate consignees)



(for distribution to ultimate consignees)